α-(4-methoxymethoxy-3,5-di-tert-butylphenyl)-N-tert-butylnitrone

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: α-(4-methoxymethoxy-3,5-di-tert-butylphenyl)-N-tert-butylnitrone
• 英文别名: α-(4-methoxymethoxy-3,5-di-tert-butyl-phenyl)-N-tert-butylnitrone；α-[4-methoxymethoxy-3,5-di-tert-butylphenyl)-N-tert-butylnitrone；N-tert-butyl-1-[3,5-ditert-butyl-4-(methoxymethoxy)phenyl]methanimine oxide
• 化学式: C₂₁H₃₅NO₃
• 分子量: 349.514
• InChiKey: DZXFXGVAEIDJGX-XKZIYDEJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  47.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-叔丁基羟胺 、 3,5-二-叔丁基-4-(甲氧基甲氧基)苯甲醛 以 苯 为溶剂， 反应 72.0h， 以69%的产率得到α-(4-methoxymethoxy-3,5-di-tert-butylphenyl)-N-tert-butylnitrone
  参考文献：
  名称：

  [EN] METHODS FOR TREATING MULTIPLE SCLEROSIS AND PHARMACEUTICAL COMPOSITIONS THEREFOR
  [FR] METHODES DE TRAITEMENT DE LA SCLEROSE EN PLAQUES ET COMPOSITIONS PHARMACEUTIQUES ASSOCIEES

  摘要：

  本发明涉及一种用于治疗或预防趋化因子介导疾病的药物组合物，例如多发性硬化或相关疾病，其中含有3,4,5-三取代芳基亚硝基酮，并且提供了治疗或预防多发性硬化和相关疾病的方法。3,4,5-三取代芳基亚硝基酮具有公式：I，其中R'-R3和Q如规范所定义，或3,4,5-三取代芳基亚硝基酮具有公式：其中R1-R3和Q如规范所定义。

  公开号：

  WO2005087214A1

文献信息

• Use of aryl nitrone compounds in methods for treating neuropathic pain
  申请人：——

  公开号：US20020165274A1

  公开（公告）日：2002-11-07

  3,4,5-trisubstituted aryl nitrone compounds having the formula: 1 where R 1 —R 4 are as defined in the specification are useful as therapeutics for neuropathic pain conditions in mammals.

  具有以下公式的3,4,5-三取代芳基亚硝基化合物：其中R1—R4如规范中定义的，对哺乳动物的神经病性疼痛症状具有治疗作用。
• 3,4,5-Trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
  申请人：RENOVIS, INC.

  公开号：US20040198835A1

  公开（公告）日：2004-10-07

  Disclosed are 3,4,5-trisubstituted aryl nitrone compoundsd and pharmaceutical compositions containing such compounds. The 3,4,5-trisubstituted aryl nitrone compounds have formula (I); where R 1 -R 4 are as defined in the specification. The disclosed compositions are useful as therapeutics for inflammation-related conditions in mammals, such as arthritis, and as analytical reagents for detecting free radicals.

  本发明涉及3,4,5-三取代基芳基亚硝基化合物及含有此类化合物的医药组合物。3,4,5-三取代基芳基亚硝基化合物的化学式为(I)，其中R1-R4如规范中定义。所述组合物可用于哺乳动物的与炎症相关的疾病，例如关节炎等治疗，并可作为检测自由基的分析试剂。
• 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
  申请人：——

  公开号：US20030078297A1

  公开（公告）日：2003-04-24

  Disclosed are 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing such compounds. The 3,4,5-trisubstituted aryl nitrone compounds have formula (I); where R 1 -R 4 are as defined in the specification. The disclosed compositions are useful as therapeutics for inflammation-related conditions in mammals, such as arthritis, and as analytical reagents for detecting free radicals.

  本发明涉及3,4,5-三取代芳基亚硝基化合物和含有这种化合物的制药组合物。3,4,5-三取代芳基亚硝基化合物具有式（I），其中R1-R4如规范中所定义。所披露的组合物可用作哺乳动物炎症相关疾病（如关节炎）的治疗药物，以及用于检测自由基的分析试剂。
• Methods for treating multiple sclerosis and pharmaceutical compositions therefor
  申请人：Kelly G. Michael

  公开号：US20050215646A1

  公开（公告）日：2005-09-29

  Disclosed are pharmaceutical compositions for the treatment or prevention of chemokine mediated conditions, such as multiple sclerosis or related conditions, containing 3,4,5-trisubstituted aryl nitrones, and methods for the treatment or prevention of multiple sclerosis and related conditions. The 3,4,5-trisubstituted aryl nitrones have the formula: where R 1 -R 3 and Q are as defined in the specification, or the 3,4,5-trisubstituted aryl nitrones have the formula: where R 1 -R 3 and Q are as defined in the specification.

  本发明涉及一种药物组合物，用于治疗或预防趋化因子介导的疾病，例如多发性硬化或相关疾病，包含3,4,5-三取代芳基硝酮，并提供了治疗或预防多发性硬化和相关疾病的方法。3,4,5-三取代芳基硝酮的化学式如下：其中R1-R3和Q如规范中所定义，或者3,4,5-三取代芳基硝酮的化学式如下：其中R1-R3和Q如规范中所定义。
• 3,4,5-TRISUBSTITUTED ARYL NITRONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
  申请人：Centaur Pharmaceuticals, Inc.

  公开号：EP1135367A1

  公开（公告）日：2001-09-26